Medical management of crohn disease

Clinics in Colon and Rectal Surgery

Volumn 26, Issue 2, 2013, Pages 67-74

  Scott, Frank I ^a   Osterman, Mark T ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

5 aminosalicylic acid; antitumor necrosis factor alpha; budesonide; Crohn disease; immunomodulators

Indexed keywords

EID: 84879613385     PISSN: 15310043     EISSN: 15309681     Source Type: Journal    
DOI: 10.1055/s-0033-1348043     Document Type: Article

References (60)

1. Caprilli R., Cesarini M., Angelucci E., Frieri G. The long journey of salicylates in ulcerative colitis: The past and the future. J Crohn's Colitis: 2009; 3 3 149 156
2. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology: 1973; 64 2 240 245
3. Bantel H., Berg C., Vieth M., Stolte M., Kruis W., Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol: 2000; 95 12 3452 3457
4. Haskó G., Szabó C., Németh Z. H., Deitch E. A. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology: 2001; 103 4 473 478
5. Kaiser G. C., Yan F., Polk D. B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology: 1999; 116 3 602 609
6. Lim W. C., Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev: 2010; 12 CD008870
7. Edsbäcker S., Andersson P., Lindberg C., Paulson J., Ryrfeldt A., Thalén A. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos: 1987; 15 3 403 411
8. Greenberg G. R., Feagan B. G., Martin F., et al. Canadian Inflammatory Bowel Disease Study Group Oral budesonide for active Crohn's disease. N Engl J Med: 1994; 331 13 836 841
9. Campieri M., Ferguson A., Doe W., Persson T., Nilsson L. G. The Global Budesonide Study Group Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut: 1997; 41 2 209 214
10. Seow C. H., Benchimol E. I., Griffiths A. M., Otley A. R., Steinhart A. H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev: 2008; 3 CD000296
11. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut: 1994; 35 3 360 362
12. Modigliani R., Mary J. Y., Simon J. F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology: 1990; 98 4 811 818
13. Maltzman J. S., Koretzky G. A. Azathioprine: old drug, new actions. J Clin Invest: 2003; 111 8 1122 1124
14. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest: 2003; 111 8 1133 1145
15. Dubinsky M. C., Lamothe S., Yang H. Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology: 2000; 118 4 705 713
16. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet: 1980; 32 5 651 662
17. Prefontaine E., Macdonald J. K., Sutherland L. R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev: 2010; 6 CD000545
18. Prefontaine E., Sutherland L. R., Macdonald J. K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev: 2009; 1 CD000067
19. Osterman M. T., Kundu R., Lichtenstein G. R., Lewis J. D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology: 2006; 130 4 1047 1053
20. Haines M. L., Ajlouni Y., Irving P. M., et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis: 2011; 17 6 1301 1307
21. Beaugerie L., Brousse N., Bouvier A. M., et al. CESAME Study Group Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet: 2009; 374 9701 1617 1625
22. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Cesame Study Group Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology: 2011; 141 5 1621 1628, e1-e5
23. Long M. D., Martin C. F., Pipkin C. A., Herfarth H. H., Sandler R. S., Kappelman M. D. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology: 2012; 143 2 390 399, e1
24. Singh H., Nugent Z., Demers A. A., Bernstein C. N. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology: 2011; 141 5 1612 1620
25. Long M. D., Herfarth H. H., Pipkin C. A., Porter C. Q., Sandler R. S., Kappelman M. D. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol: 2010; 8 3 268 274
26. Cutolo M., Sulli A., Pizzorni C., Seriolo B., Straub R. H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis: 2001; 60 8 729 735
27. Feagan B. G., Rochon J., Fedorak R. N., et al. The North American Crohn's Study Group Investigators Methotrexate for the treatment of Crohn's disease. N Engl J Med: 1995; 332 5 292 297
28. Alfadhli A. A., McDonald J. W., Feagan B. G. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev: 2005; 1 CD003459
29. Feagan B. G., Fedorak R. N., Irvine E. J., et al. North American Crohn's Study Group Investigators A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med: 2000; 342 22 1627 1632
30. Khan N., Abbas A. M., Whang N., Balart L. A., Bazzano L. A., Kelly T. N. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis: 2012; 18 2 359 367
31. Van den Brande J. M., Braat H., van den Brink G. R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology: 2003; 124 7 1774 1785
32. ten Hove T., van Montfrans C., Peppelenbosch M. P., van Deventer S. J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut: 2002; 50 2 206 211
33. Lügering A., Schmidt M., Lügering N., Pauels H. G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology: 2001; 121 5 1145 1157
34. Knight D. M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol: 1993; 30 16 1443 1453
35. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis: 1999; 58 01 I70 I72
36. Sandborn W. J., Feagan B. G., Stoinov S., et al. PRECISE 1 Study Investigators Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med: 2007; 357 3 228 238
37. Targan S. R., Hanauer S. B., van Deventer S. J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med: 1997; 337 15 1029 1035
38. Hanauer S. B., Feagan B. G., Lichtenstein G. R., et al. ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet: 2002; 359 9317 1541 1549
39. Hanauer S. B., Sandborn W. J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology: 2006; 130 2 323 333, quiz 591
40. Sandborn W. J., Hanauer S. B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut: 2007; 56 9 1232 1239
41. Colombel J. F., Sandborn W. J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology: 2007; 132 1 52 65
42. Sandborn W. J., Abreu M. T., D'Haens G., et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol: 2010; 8 8 688 695, e2
43. Lichtenstein G. R., Rutgeerts P., Sandborn W. J., et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol: 2012; 107 7 1051 1063
44. Colombel J. F., Sandborn W. J., Reinisch W., et al. SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med: 2010; 362 15 1383 1395
45. Thia K. T., Mahadevan U., Feagan B. G., et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis: 2009; 15 1 17 24
46. Present D. H., Korelitz B. I., Wisch N., Glass J. L., Sachar D. B., Pasternack B. S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med: 1980; 302 18 981 987
47. Present D. H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med: 1999; 340 18 1398 1405
48. Sands B. E., Anderson F. H., Bernstein C. N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med: 2004; 350 9 876 885
49. Sands B. E., Blank M. A., Patel K., van Deventer S. J. ACCENT II Study Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol: 2004; 2 10 912 920
50. Schreiber S., Lawrance I. C., Thomsen O. O., Hanauer S. B., Bloomfield R., Sandborn W. J. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther: 2011; 33 2 185 193
51. Ochsenkühn T., Göke B., Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol: 2002; 97 8 2022 2025
52. Schröder O., Blumenstein I., Schulte-Bockholt A., Stein J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther: 2004; 19 3 295 301
53. Regueiro M., Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis: 2003; 9 2 98 103
54. Sciaudone G., Di Stazio C., Limongelli P., et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg: 2010; 53 5 299 304
55. Nguyen G. C., Nugent Z., Shaw S., Bernstein C. N. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology: 2011; 141 1 90 97
56. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology: 1995; 108 6 1617 1621
57. Rutgeerts P., Van Assche G., Vermeire S., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology: 2005; 128 4 856 861
58. Hanauer S. B., Korelitz B. I., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology: 2004; 127 3 723 729
59. D'Haens G. R., Vermeire S., Van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology: 2008; 135 4 1123 1129
60. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology: 2009; 136 2 441 450, e1, quiz 716